Glioma oncogenesis in the constitutional mismatch repair deficiency (CMMRD) syndrome

IF 3.7 Q1 CLINICAL NEUROLOGY Neuro-oncology advances Pub Date : 2024-07-11 DOI:10.1093/noajnl/vdae120
L. Guerrini-Rousseau, Jane Merlevede, Philippe Denizeau, F. Andreiuolo, Pascale Varlet, S. Puget, K. Beccaria, T. Blauwblomme, O. Cabaret, N. Hamzaoui, Franck Bourdeaut, Cécile Faure-Conter, Martine Muleris, C. Colas, Tiphaine Adam de Beaumais, D. Castel, Etienne Rouleau, L. Brugières, Jacques Grill, Marie-Anne Debily
{"title":"Glioma oncogenesis in the constitutional mismatch repair deficiency (CMMRD) syndrome","authors":"L. Guerrini-Rousseau, Jane Merlevede, Philippe Denizeau, F. Andreiuolo, Pascale Varlet, S. Puget, K. Beccaria, T. Blauwblomme, O. Cabaret, N. Hamzaoui, Franck Bourdeaut, Cécile Faure-Conter, Martine Muleris, C. Colas, Tiphaine Adam de Beaumais, D. Castel, Etienne Rouleau, L. Brugières, Jacques Grill, Marie-Anne Debily","doi":"10.1093/noajnl/vdae120","DOIUrl":null,"url":null,"abstract":"\n \n \n Constitutional Mismatch Repair Deficiency (CMMRD) is a cancer predisposition due to biallelic mutations in one of the mismatch repair (MMR) genes associated with early onset of cancers, especially high-grade gliomas. Our aim was to decipher the molecular specificities of these gliomas.\n \n \n \n Clinical, histopathological and whole exome sequencing data were analyzed in 12 children with genetically proven CMMRD and a high-grade glioma.\n \n \n \n PDL1 expression was present on immunohistochemistry in 50% of the samples. In 9 patients, the glioma harbored an ultra-hypermutated phenotype (104-635 coding single nucleotide variants (SNV) per Mb, median 204). Driver mutations in POLE and POLD1 exonuclease domains were described for 8 and 1 patients respectively and were always present in the mutation burst with the highest variant allele frequency (VAF). The mutational signatures were dominated by MMR-related ones and similar in the different mutation bursts of a same patient without subsequent enrichment of the mutation signatures with POL-driven ones. Median number of coding SNV with VAF above the one of the driving polymerase mutation per Mb was 57 (17-191). Our findings suggest that somatic polymerase alterations does not entirely explain the ultra-hypermutant phenotype. SETD2, TP53, NF1, EPHB2, PRKDC and DICER1 genes were frequently mutated with higher VAF than the deleterious somatic polymerase mutation.\n \n \n \n CMMRD-associated gliomas have a specific oncogenesis that does not involve usual pathways and mutations seen in sporadic pediatric or adult glioblastomas. Frequent alterations in other pathways such as MAPK may suggest the use of other targeted therapies along with PD1 inhibitors.\n","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology advances","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.1093/noajnl/vdae120","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Constitutional Mismatch Repair Deficiency (CMMRD) is a cancer predisposition due to biallelic mutations in one of the mismatch repair (MMR) genes associated with early onset of cancers, especially high-grade gliomas. Our aim was to decipher the molecular specificities of these gliomas. Clinical, histopathological and whole exome sequencing data were analyzed in 12 children with genetically proven CMMRD and a high-grade glioma. PDL1 expression was present on immunohistochemistry in 50% of the samples. In 9 patients, the glioma harbored an ultra-hypermutated phenotype (104-635 coding single nucleotide variants (SNV) per Mb, median 204). Driver mutations in POLE and POLD1 exonuclease domains were described for 8 and 1 patients respectively and were always present in the mutation burst with the highest variant allele frequency (VAF). The mutational signatures were dominated by MMR-related ones and similar in the different mutation bursts of a same patient without subsequent enrichment of the mutation signatures with POL-driven ones. Median number of coding SNV with VAF above the one of the driving polymerase mutation per Mb was 57 (17-191). Our findings suggest that somatic polymerase alterations does not entirely explain the ultra-hypermutant phenotype. SETD2, TP53, NF1, EPHB2, PRKDC and DICER1 genes were frequently mutated with higher VAF than the deleterious somatic polymerase mutation. CMMRD-associated gliomas have a specific oncogenesis that does not involve usual pathways and mutations seen in sporadic pediatric or adult glioblastomas. Frequent alterations in other pathways such as MAPK may suggest the use of other targeted therapies along with PD1 inhibitors.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
体质错配修复缺陷(CMMRD)综合征的胶质瘤致癌机制
体质性错配修复缺陷(CMMRD)是一种因错配修复(MMR)基因之一的双重复突变而导致的癌症易感性,与癌症的早发有关,尤其是高级别胶质瘤。我们的目标是破译这些胶质瘤的分子特异性。 我们分析了12名经基因证实患有CMMRD和高级别胶质瘤的儿童的临床、组织病理学和全外显子组测序数据。 50%的样本在免疫组化中出现了PDL1表达。9名患者的胶质瘤具有超高突变表型(每Mb有104-635个编码单核苷酸变异(SNV),中位数为204个)。POLE和POLD1外切酶结构域的驱动基因突变分别出现在8例和1例患者中,并且总是出现在变异等位基因频率(VAF)最高的突变群中。突变特征以 MMR 相关特征为主,且在同一患者的不同突变暴发中具有相似性,突变特征随后并未富集为 POL 驱动的特征。每 Mb VAF 值高于驱动聚合酶突变的编码 SNV 的中位数为 57(17-191)。我们的研究结果表明,体细胞聚合酶改变并不能完全解释超高突变表型。与有害的体细胞聚合酶突变相比,SETD2、TP53、NF1、EPHB2、PRKDC 和 DICER1 基因突变的 VAF 更高。 CMMRD相关胶质瘤有其特定的致癌机制,不涉及散发性儿童或成人胶质母细胞瘤中常见的通路和突变。MAPK等其他通路的频繁改变可能建议在使用PD1抑制剂的同时使用其他靶向疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊最新文献
International symposium on inheritable central nervous system (CNS) cancer predisposition: A prologue. Correction to: Effect of bevacizumab on refractory meningiomas: 3D volumetric growth rate versus response assessment in neuro-oncology criteria. Effect of antibiotic drug use on outcome and therapy-related toxicity in patients with glioblastoma-A retrospective cohort study. Empowering the next generation in neuro-oncology: Introduction of the EANO Career Boost Initiative. A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1